Effects of pioglitazone and metformin on β-cell function in nondiabetic subjects at high risk for type 2 diabetes

被引:20
|
作者
Rasouli, Neda
Kern, Philip A.
Reece, E. Albert
Elbein, Steven C.
机构
[1] Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA
[2] Univ Arkansas Med Sci, Coll Med, Dept Med, Div Endocrinol, Little Rock, AR USA
[3] Univ Arkansas Med Sci, Coll Med, Dept Obstet & Gynecol, Little Rock, AR USA
关键词
insulin sensitizer; prediabetes;
D O I
10.1152/ajpendo.00221.2006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Effects of pioglitazone and metformin on beta-cell function in nondiabetic subjects at high risk for type 2 diabetes. Am J Physiol Endocrinol Metab 292:E359-E365, 2007. First published September 12, 2006;doi:10.1152/ajpendo.00221.2006. Thiazolidinediones (TZDs) and metformin decreased the incidence of diabetes in subjects at risk for developing diabetes and improved peripheral or hepatic insulin sensitivity, respectively. Whether they also directly improved beta-cell function is not clear. In vitro studies showed improved beta-cell function in response to TZDs and metformin; however, the effects of TZDs or metformin on beta-cell function in humans are still uncertain. We hypothesized that both TZDs and metformin directly affect beta-cell function. We evaluated beta-cell function and insulin sensitivity (SI) in subjects with impaired glucose tolerance or a history of gestational diabetes using oral and intravenous glucose tolerance tests in addition to the glucose-potentiated arginine stimulation test. In contrast to metformin, pioglitazone improved S-I, glucose tolerance, and insulin-independent glucose disposal [glucose effectiveness (SG)]. Neither pioglitazone nor metformin significantly improved beta-cell compensation for insulin resistance [disposition index (DI)], but the change in DI significantly correlated with baseline SI. Insulin secretion in response to arginine at maximally potentiating glucose levels (AIR(max)) tended to increase after metformin and to decrease after pioglitazone; however, when adjusted for SI, the changes were not significant. Our results demonstrate that, in nondiabetic subjects at risk for diabetes, pioglitazone, but not metformin, significantly improved glucose tolerance by improving SI and SG. We did not find any evidence that either pioglitazone or metformin improved beta-cell function. Improved beta-cell compensation was observed primarily in the subgroup of subjects that had the lowest SI at baseline.
引用
收藏
页码:E359 / E365
页数:7
相关论文
共 50 条
  • [31] THE EFFECTS OF PIOGLITAZONE AND METFORMIN ON SERUM DPP-4 LEVELS IN TYPE 2 DIABETES MELLITUS
    Tanaka, S.
    Kanazawa, I.
    Notsu, M.
    Sugimoto, T.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 : S147 - S147
  • [32] Effect of alogliptin combined with pioglitazone on beta cell function and insulin resistance in metformin-treated patients with type 2 diabetes
    Burant, C.
    Fleck, P.
    Wilson, C.
    Mekki, Q.
    Pratley, R.
    DeFronzo, R.
    DIABETOLOGIA, 2009, 52 : S314 - S315
  • [33] Effects of exenatide plus rosiglitazone on measures of beta cell function and insulin sensitivity in subjects with type 2 diabetes previously treated with metformin
    Glass, L. C.
    Triplitt, C.
    Lewis, M. S.
    Qu, Y.
    Guo, Y.
    Maggs, D.
    DeFronzo, R. A.
    DIABETOLOGIA, 2009, 52 : S286 - S286
  • [34] Weight changes with treatment of type 2 diabetes with pioglitazone, metformin and gficlazide
    Belcher, G
    Edwards, G
    Urquhart, R
    Eckland, D
    Johns, D
    Tan, MG
    DIABETES, 2003, 52 : A111 - A111
  • [35] The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes
    Economides, PA
    Caselli, A
    Tiani, E
    Khaodhiar, L
    Horton, ES
    Veves, A
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (02): : 740 - 747
  • [36] Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes
    Belcher, G
    Lambert, C
    Edwards, G
    Urquhart, R
    Matthews, DR
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2005, 70 (01) : 53 - 62
  • [37] Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
    Holland, Daniel Q.
    Neumiller, Joshua J.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2014, 7 : 277 - 288
  • [38] THE EFFECTS OF METFORMIN ON THE FIBRINOLYTIC SYSTEM IN DIABETIC AND NONDIABETIC SUBJECTS
    GRANT, PJ
    DIABETES & METABOLISM, 1991, 17 (1BIS): : 168 - 173
  • [39] Effects of pioglitazone on liver function in comparison to gliclazide in patients with type 2 diabetes
    Perriello, G
    Pampanelli, S
    Di Pietro, C
    Brunetti, P
    DIABETES, 2004, 53 : A141 - A141
  • [40] Pioglitazone versus gliclazide addition in secondary failure to metformin alone in Type 2 diabetes: beneficial effects of pioglitazone on lipoproteins and inflammation
    Jenkins, A
    Karschimkus, C
    Dragicevic, G
    Rowley, K
    Wolthers, T
    Best, JD
    DIABETOLOGIA, 2004, 47 : A410 - A410